Evidence from observational studies Natalizumab

from Presentation-Paediatric onset multiple sclerpsis

by paradigms

First line therapy with DMT with moderate efficacy

A large real-world NATALIZUMAB study

101 POMS

45 treatment naive, 67 switched from 1 line injectables, 7 from immunosupressants

Significant reduction of ARR from 2.3 to 0.1 during the follow op mean of 3 yeras

Free of any clinical or MRI activity 58%

No significant occurrences of AE

The pharmacokinetic/pharmacodynamic properties and the real-world efficacy/safety data are similar to those adults

Ghezzi A, Moiola L, Pozzilli C, Brescia-Morra V, Gallo P, Gri- maldi LM, et al. Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. 2015 ; Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J. The use of natalizumab in pediatric patients with active relapsing multiple sclerosis: a prospective study. Pediatr Neurol. 201

Evidence from observational studies Natalizumab

Next Article

First line therapy with DMT with moderate efficacy

More articles from this publication:

First line therapy with DMT with moderate efficacy

Recommendations for DMT in POMS

Treatment of MS in children

Different acquired demyelinating syndrome presentations

Diagnostic criteria for paediatric MS

Monitoring of treatment

Considerations on future treatment of POMS

Experience with B cell depleting DMT

Experience with Rituximab from observational studies

This article is from:

Presentation-Paediatric onset multiple sclerpsis